Comparing 5 approaches for cannabis

Inclusion

• +Between 21 and 49 years of age, inclusively;
• +Have used cannabis at least once in their lifetime and have used cannabis three days or less in the 30 days prior to enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →;
• +Be able to provide a signed informed consentInformed consentThe process of being told what taking part involves, then choosing freely.Read more →;
• +Willing to comply with study procedures and requirements as per protocolProtocolThe detailed plan a study must follow.Read more →;
• +Have a forced expiratory volume in first second (FEV) less than or equal to 90 %;
• +Able to communicate and understand English or French language;
• +For female participants:
• +Exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more →
• +Participants will be excluded if any of the following criteria are met:
• +Any disabling medical condition, as assessed by medical history, physical exam, vital signs and/or laboratory assessments that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent;
• +Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or current suicidality based on the Mini International Neuropsychiatric Interview);
• +Any other disabling, unstable or acute mental condition that, in the opinion of the study physician, precludes safe participation in the study or ability to provide fully informed consent;
• +Known chronic liver disease or aspartate transaminase/alanine transaminase (AST/ALT) two times higher than upper limit of normal values at screening visitScreeningThe checks done before joining, to see whether a study fits.Read more →;
• +Blood pressure higher than 130/80 mmHg;
• +Kidney disorders;
• +Bleeding disorders;
• +Pending legal action or other reason that, in the opinion of the study physician, might prevent study completion;
• +Use of medication within 7 days of experimental sessions; which, in the opinion of the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →, may interact with cannabis.
• +Participation in clinical studies or undergoing other investigational procedure involving cannabis or cannabinoids administration within 30 days prior to randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more →.
• +Resting heart rate over 100 beats per minute.
• +Current body mass index (BMI) over 29.9 kg/m2.
• +Any clinically significant electrocardiogram abnormalities at screening visit.
• +a. No childbearing potential, defined as: i. postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or ii. Documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or b. For female of childbearing potential: i. Must have negative pregnancy test result at screening and at subsequent visits.
• +ii. AND have no pregnancy plan while on the study iii. AND must agree to use a medically accepted method of birth controlControl groupThe group a new treatment is measured against.Read more → throughout the study.
• +Currently pregnant, breastfeeding or planning to become pregnant either at screening or while enrolled in the study;
• +Current moderate or severe DSM-5 substance use disorder (except nicotine) according to SCID-V;